USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
08 Sep 2021 | 02:45 PM GMT

DTx Last Mile Delivery: Adoption by HCPs and Patients

Anchored by:

Nikos Green
Senior Venture Architect & PO Neuroscience
ROX HEALTH GMBH

Participants:

Nikos Green Senior Venture Architect & PO NeuroscienceRoX Health GmbH
Nikos Green
Senior Venture Architect & PO NeuroscienceRoX Health GmbH
Ahmed Albaiti CEOZS Associates
Ahmed Albaiti
CEOZS Associates
Ahmed Albaiti PrincipalZS
Ahmed Albaiti
PrincipalZS
Chris Cera CEOArcweb Technologies
Chris Cera
CEOArcweb Technologies
JM
john mattison CMIOACP
JM
john mattison
CMIOACP
Krys Zaluski Director, External GrowthBiogen
Krys Zaluski
Director, External GrowthBiogen
Larisa Rashid Director of MarketingCognito Therapeutics, Inc.
Larisa Rashid
Director of MarketingCognito Therapeutics, Inc.

About this Meeting

While the DTx market is growing exponentially, the scale of usage from the physician and patient cohorts remains low.  Despite proven clinical outcomes, regulatory approvals, usage and spread remains slim. For example, even though German DiGA has 19 approved products so far, their prescription and adoption have not taken off yet. Join us in this informal conversation where we will discuss the main challenges around HCP and Patient adoption of DTx; we will talk about:  

  •  Current levels of prescription and adoption of DTx 
  •  How to increase HCP and patient awareness, drive activation and ensure the proper onboarding to DTx products 
  •  DTx integration into physicians’ tools (like EMR, CDSS, etc) and workflow: challenges and best practices 
  •  Next steps the industry needs to make to improve DTx last mile delivery